FI
TVTX icon

Fosun International’s Travere Therapeutics TVTX Stock Holding History

Fosun International’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-56,837
Closed -$1.14M – 290
2019
Q2 		$1.14M Hold
56,837
– – 0.08% 153
2019
Q1 		$1.31M Hold
56,837
– – 0.08% 135
2018
Q4 		$1.26M Buy
+56,837
New +$1.41M 0.08% 117

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Fosun International's TVTX Position: Q3 2019 in Review

Fosun International sold out of Travere Therapeutics (TVTX) in Q3 2019, closing a stake of 56,837 shares — an estimated $1.14M sold.

Fosun International first reported a position in TVTX in Q4 2018 and held it in 3 quarters. The position peaked at $1.31M in Q1 2019. 130 funds tracked by Wall St. Rank hold TVTX as of Q3 2019.

  • Fosun International reported no remaining Travere Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 56,837 Travere Therapeutics shares in Q3 2019, an estimated $1.14M.
  • Fosun International first reported a position in Travere Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Travere Therapeutics position peaked at $1.31M in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.